The conversation discusses adding finasteride (Propecia) to a liquid containing stemoxydine for hair loss treatment. The user is inquiring about the effectiveness of this combination.
The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.
The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.
The conversation discusses the storage and use of pyrilutamide for hair loss, where one user advises against keeping it in the freezer as it may crystallize the active compounds.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
A 42-year-old experienced significant hair regrowth after 12 weeks on an oral combination of finasteride (1 mg) and minoxidil (2.5 mg), with noticeable improvements and no side effects. The user is considering continuing the treatment for a year due to the unexpected positive results.
The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
Korean scientists developed a red light therapy that reduces a hair loss marker by 92%. Users discussed the benefits and drawbacks of natural sunlight versus red light caps for hair health, with some suggesting supplements for vitamin D.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.
The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.
Ethosomes are suggested as an effective delivery method for topical finasteride solutions, requiring the addition of a phospholipid like soya lecithins. The user questions why do-it-yourself solutions don't commonly use ethosomes despite their potential benefits.
Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.
The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.
The conversation is about obtaining custom-compounded topical finasteride in Germany due to side effects from oral finasteride. The user seeks a lower concentration solution separate from minoxidil, and others suggest self-mixing or trying alternatives like dutasteride.
Chlorine dioxide was discussed as a potential hair growth treatment, with a method involving spraying it on the scalp and covering it with a cap. Concerns were raised about its safety, comparing it to bleach.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
A 31-year-old uses Minoxidil, RU58841, Reviv Hair Serum, and Ketoconazole shampoo for hair loss but avoids finasteride. They plan to reintroduce red light therapy (LLLT) and Eucapil despite previous shedding concerns.
Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.
Finasteride has shown great results for hair loss. The discussion also inquires about the effectiveness and side effects of Low-Level Laser/Light Therapy (LLLT).
The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.
The user saw hair improvement with minoxidil, finasteride, and a red light cap, noting better results after adding finasteride and stressing routine consistency.
The conversation discusses how to use fluridil/topilutamide with other hair loss treatments like liquid minoxidil and CB-03-01, considering fluridil's hydrophobic nature and potential degradation with water. The user questions the necessity of washing hair only once per week as suggested by the manufacturer.
The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.
The post discusses diluting 100ml of 0.1% topical finasteride with 90ml of stemoxydine to create a 0.05% solution, aiming for a longer-lasting and potentially less side-effect-prone treatment. The user seeks feedback on this idea.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.